247 Genetics

Stanford University biological engineer, discusses the field of synthetic biology

<center>

<object width=”375″ height=”305″><param name=”movie” value=”http://www.youtube.com/v/Fv0hV-gWwGY&hl=en&fs=1&color1=0×5d1719&color2=0xcd311b”></param><param name=”allowFullScreen” value=”true”></param><param name=”allowscriptaccess” value=”always”></param><embed src=”http://www.youtube.com/v/Fv0hV-gWwGY&hl=en&fs=1&color1=0×5d1719&color2=0xcd311b” type=”application/x-shockwave-flash” allowscriptaccess=”always” allowfullscreen=”true” width=”375″ height=”305″></embed></object>

</center>

Rosanne Ott, portfolio manager for the four star Alger Health Sciences Fund, says health care stocks will benefit during President Obama’s first 100 days in office, especially generic drug-makers Teva and Mylan.

CEO Ian Curry discusses DNA Genotek.

Dr. Patrick Dixon talks about gene mutations and disorders. For more of Dr. Dixon’s videos go to globalchange.com